Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04134247
Recruitment Status : Not yet recruiting
First Posted : October 22, 2019
Last Update Posted : October 22, 2019
Sponsor:
Information provided by (Responsible Party):
Wang Xin, Shandong Provincial Hospital

Brief Summary:
Lymphoma is one of the fastest growing malignancies in the world, with an annual incidence rate of about 4%. Non-Hodgkin's lymphoma (NHL) is highly heterogeneous and can be broadly divided into two major categories, B-cell lymphoma and T/NK cell lymphoma. It is composed of diseases of different pathological types and malignant degrees, and the prognosis is not the same.The anti-PD-1 antibody may benefit patients with relapsed or refractory Hodgkin's lymphoma. At the same time, in non-Hodgkin's lymphoma, PD1 antibodies also show promising therapeutic prospects. We propose this research program, based on the previous research at home and abroad, to further clarify the role of PD-1 monoclonal antibody combined with chemotherapy in the treatment of relapsed and refractory NHL patients, evaluate its clinical efficacy and safety, and explore The best treatment strategy for patients with relapsed and refractory NHL in China.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory Non-Hodgkin's Lymphoma Drug: PD-1 combined with chemotherapy Drug: chemotherapy Phase 4

Detailed Description:

Lymphoma is one of the fastest growing malignancies in the world, with an annual incidence rate of about 4%. In recent years, the incidence of malignant lymphoma in China has increased rapidly. It has risen to the ninth place among the top ten high-incidence tumors in men, and the female has risen to the eleventh place. In 2011, the incidence of lymphoma in the country has reached 6.43/100,000.

According to the characteristics of clinicopathology, lymphoma is divided into two categories: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). HL is a single disease, relatively rare, but the prognosis is good, and patients with limited period have no progress for 5 years. The survival rate was 85-95%, and the 5-year progression-free survival rate of advanced patients was 30-85%. NHL is highly heterogeneous and can be broadly divided into two major categories, B-cell lymphoma and T/NK cell lymphoma. It is composed of diseases of different pathological types and malignant degrees, and the prognosis is not the same.

In recent years, immunological checkpoint inhibitors have been the focus of research in the field of malignant tumor treatment. In clinical trials, PD-1/PD-L1 was found to be abnormally expressed in various lymphomas, including T-cell lymphoma, mediastinal large B-cell lymphoma, classical Hodgkin's lymphoma (CHL), and large variability. Cell lymphoma. Previous studies have evaluated the effects of antibody-based drugs against PD-1 (such as navobizumab and pabuleizumab) in patients with relapsed or refractory classic Hodgkin's lymphoma, and A higher response rate is shown and the security feature is acceptable. The domestic ORIENT-1 study showed that ididilimumab was highly active in patients with relapsed or refractory classic Hodgkin's lymphoma in China, and 80% (74/92) patients had an objective response. No patients died during the study. Of the 96 patients treated, 89 (93%) had treatment-related adverse events, including 17 (18%) patients with grade 3 or 4 treatment-related adverse events, and 11 patients (11%) experienced severe Adverse events, but no unexpected or off-target safety signals were found. Therefore, PD1 antibodies may benefit patients with relapsed or refractory Hodgkin's lymphoma.

At the same time, in non-Hodgkin's lymphoma, PD1 antibodies also show promising therapeutic prospects. Clinical studies at home and abroad have shown that PD-1 inhibitors are effective in relapsed or refractory extranodal NKT lymphoma. The results of the Idiliumab ORIENT-4 test showed that 1 year OS 82.1%, ORR 67.9%, DCR 85.7%, and PD-1 inhibitor combined with citabin to treat relapsed or refractory extranodal NKT is underway; PD-1 inhibitor monotherapy for relapsed or refractory PTCL is generally effective (ORR 33%, 4 of them CR); PD-1 inhibitor monotherapy is effective in treating relapsed or refractory mycosis/Sezary syndrome (ORR) 37.5%) has been recommended by the NCCN guidelines; trials in combination with IFN γ-1b are underway. PD-1 inhibitor monotherapy for relapsed or refractory PMBCL or PCNSL is effective, and PD-1 inhibitors have been recommended by the NCCN guidelines for the former treatment.

Therefore, we propose this research program, based on the previous research at home and abroad, to further clarify the role of PD-1 monoclonal antibody combined with chemotherapy in the treatment of relapsed and refractory NHL patients, evaluate its clinical efficacy and safety, and explore The best treatment strategy for patients with relapsed and refractory NHL in China.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Estimated Study Start Date : November 1, 2019
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : November 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: PD-1 combined with chemotherapy
21 days every cycle, assessment after 3-cycle
Drug: PD-1 combined with chemotherapy

PD-1 200 mg,d1; Rituximab 375mg/m2,d0( the same as the chemotherapy group)

The chemotherapy chooses one of the following:

GDP:Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx:Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2,d1; DA-EPOCH:Epirubicin 15mg/m2 ,d1-4; Etoposide 50mg/m2 ,d1-4; Vincristine 0.4mg/ m2 ,d1-4; Cyclophosphamide 750mg/ m2 , d5; Prednisone 60mg/m2/d, d1-5; ICE: Ifosfamide 1g/m2,d1-4; Cisplatin 25mg/m2, d1-4; Etoposide 60 mg/m2,d1-4; DICE: Ifosfamide 1 g/m2,dl-d4; Cisplatin 25mg/m2, d1-4; Etoposide 60 mg/m2,d1-4; Dexamethasone 10-20mg,d1-4; High dose MTX(Central recurrence):MTX 3.5g/m2,d1; Hyper CVAD(B):MTX 1g/m2, d1; Cytarabine 2-3g/m2, q12h, d2-3

Other Name: PD-1 combined with chemotherapy group

Active Comparator: chemotherapy
21 days every cycle, assessment after 3-cycle
Drug: chemotherapy

Rituximab 375mg/m2,d0( Except for patients who relapsed within12 months after the last application of rituximab)

The chemotherapy chooses one of the following:

GDP:Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx:Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2,d1; DA-EPOCH:Epirubicin 15mg/m2 ,d1-4; Etoposide 50mg/m2 ,d1-4; Vincristine 0.4mg/ m2 ,d1-4; Cyclophosphamide 750mg/ m2 , d5; Prednisone 60mg/m2/d, d1-5; ICE: Ifosfamide 1g/m2,d1-4; Cisplatin 25mg/m2, d1-4; Etoposide 60 mg/m2,d1-4; DICE: Ifosfamide 1 g/m2,dl-d4; Cisplatin 25mg/m2, d1-4; Etoposide 60 mg/m2,d1-4; Dexamethasone 10-20mg,d1-4; High dose MTX(Central recurrence):MTX 3.5g/m2,d1; Hyper CVAD(B):MTX 1g/m2, d1; Cytarabine 2-3g/m2, q12h, d2-3

Other Name: chemotherapy group




Primary Outcome Measures :
  1. Overall response rate [ Time Frame: 2 years ]
    Percentage of patients with complete remission (CR)or partial remission (PR)


Secondary Outcome Measures :
  1. Progression free survival(PFS) [ Time Frame: 2 years ]
    Time from enrollment to tumor progression or death

  2. overall survival(OS) [ Time Frame: 2 years ]
    Time from enrollment to death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Non-Hodgkin's lymphoma (NHL) confirmed by histopathology, preferably in the detection of tumor tissue PD-L1 expression.
  2. A recurrent or refractory disease defined as: 1) recurrence of disease after complete remission (CR); or 2) partial remission (PR), disease stabilization (SD), or disease Progress (PD) when the treatment is completed prior to enrollment in the study.
  3. Age≥18 years old, both men and women.
  4. The ECOG score is 0-2.
  5. There is at least one evaluable lesion (maximum diameter>15mm or shortest diameter>10mm). Preferably, PET-CT shows high metabolism of FDG.
  6. Have received appropriate first-line and more-line treatment of the corresponding NHL.
  7. Liver and kidney function: blood bilirubin≤35μmol/L, AST or ALT is less than 2 times the upper limit of normal value, serum creatinine≤150μmol/L.
  8. The thyroid function is normal.
  9. Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraception during treatment.
  10. Subjects must sign an informed consent form.

Exclusion Criteria:

  1. Age<18 years old;
  2. Received ASCT within 90 days prior to the first use of the study drug;
  3. Severe allergies, or patients known to be allergic or intolerant of the drug components of the chemotherapy regimen;
  4. Active, unrecognized or suspected autoimmune disease, or a history of autoimmune disease within 2 years;
  5. Previously exposed to any antibody against PD-1, PD-L1 or cytotoxic T lymphocyte-associated antigen 4
  6. Exposure to any study drug within 4 weeks prior to the first use of the study drug
  7. Expose to the last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy or arterial embolization) within 3 weeks prior to the first use of the study drug.
  8. Have a history of oncology and have received any treatment for this tumor in the past 3 years;
  9. Patients during pregnancy and lactation;
  10. Accompanied by severe heart disease, including acute myocardial infarction within 6 months, or in accordance with New York Heart Association cardiac function III or IV;
  11. A serological test for HIV or active hepatitis C virus is known to be positive;
  12. Hepatitis B virus carriers or hepatitis B virus DNA positive untreated patients are known;
  13. TB patients active period
  14. Other circumstances that the investigator believes are not suitable for inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04134247


Contacts
Layout table for location contacts
Contact: Wang Xin, MD,PhD +86-531-68778331 xinw8331@163.com
Contact: Ge Xueling, MD +86-531-68778331 xueling0617@126.com

Locations
Layout table for location information
China, Shandong
Department of Hematology, Shandong Provincial Hospital Recruiting
Jinan, Shandong, China, 250012
Contact: Wang Xin, MD, PHD    +86-531-68778331    xinw8331@163.com   
Contact: Ge Xueling, MD    +86-531-68778331    xueling0617@126.com   
Sponsors and Collaborators
Shandong Provincial Hospital
Investigators
Layout table for investigator information
Principal Investigator: Wang Xin, MD,PhD Shandong Provincial Hospital

Layout table for additonal information
Responsible Party: Wang Xin, Director of Department of Hematology, Shandong Provincial Hospital
ClinicalTrials.gov Identifier: NCT04134247     History of Changes
Other Study ID Numbers: ShandongPH006
First Posted: October 22, 2019    Key Record Dates
Last Update Posted: October 22, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs